Medicines For Europe Recommends Changes To EU Pharmaceutical Legislation
Prioritizes Digitalization Of Regulatory Framework And Incentivizing Manufacturing Investments
Medicines for Europe has offered several suggestions to re-evaluate the EU’s pharmaceutical legislation, including moves to allow off-patent competition from day one of exclusivity expiry as well as to ensure a competitive and balanced single market for multi-source medicines. The European off-patent industry body also discussed access issues, unmet medical needs and incentives in its feedback.
You may also be interested in...
Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.